TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12953047
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of relapse therapy
Study: 8715742
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of medicines
Study: 8715742
Drug: Previous studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous studies on self-administration
Study: 3887543
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day for 21 days
Study: 16919573
Drug: Poststress end-systolic
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poststress end-systolic volume (ESV) index greater than 27 mL/m2
Study: 16919573
Drug: Poststress ESV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poststress ESV index of 27 mL/m2 or less
Study: 11156644
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection (20 U) and subsequent daily applications of isosorbide dinitrate (ID) (2.5 mg three times daily for three months)
Study: 11156644
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection only (20 U)
Study: 7507304
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU bolus followed by 5 x 10(5) KIU/h infusion until end of surgery
Study: 28667231
Drug: Educational video
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational video about OSA and CPAP therapy
Study: 21999887
Drug: SQ-standardized grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-standardized grass allergy immunotherapy tablet (AIT)
Study: 20178207
Drug: Carbamide peroxide
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamide peroxide treatment for 14 days
Study: 27798291
Drug: Daily meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meal delivery (n = 139)
Study: 27798291
Drug: Once weekly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly, frozen meal delivery (n = 106)
Study: 24725445
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (300 mg irbesartan tablet)
Study: 24725445
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (300 mg irbesartan tablet)
Study: 23734218
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 0.8 mg / B12 0.4 mg with and without 40 mg B6
Study: 16177808
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg THC
Study: 9291340
Drug: Tenidap (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap (120 mg) daily for 6 weeks
Study: 7686709
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 30 mg/kg i.v.
Study: 17024692
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg DiaPep277
Study: 17024692
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg DiaPep277
Study: 17024692
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg DiaPep277
Study: 8485271
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg q.d.s. for 12 weeks
Study: 30892290
Drug: Guided bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided bone regeneration with dental implant placement (study group)
Study: 27737534
Drug: Gemcitabine/Cisplatin (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/Cisplatin (GP) - Gemcitabine 1,250 mg/m2 on days 1 and 8, Cisplatin 75 mg/m2 on day 1 every 3 weeks
Study: 27737534
Drug: Irinotecan/Cisplatin (IP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan/Cisplatin (IP) - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks
Study: 24671388
Drug: Ketamine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.0 mg/kg in 20 ml of normal saline)
Study: 24671388
Drug: Ketamine-levobupivacaine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine-levobupivacaine (0.5 mg/kg of ketamine plus 50.0 mg of 0.25% levobupivacaine in 20 ml of normal saline)
Study: 24671388
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 ml of intraarticular normal saline)
Study: 21777715
Drug: Armodafinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (250 mg/d)
Study: 12509398
Drug: CEE+MPA-cyclic (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+MPA-cyclic (daily CEE and MPA at 10 mg/day on days 1-12)
Study: 12509398
Drug: CEE+MPA-continuous (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+MPA-continuous (daily CEE and MPA at 2.5 mg/day)
Study: 12509398
Drug: CEE-MP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE-MP (daily CEE and micronized progesterone at 200 mg/day on days 1-12)
Study: 11025235
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) administered intravenously at up to 15 ng/kg/min for 72 hours after surgery
Study: 11025235
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline) administered for the same duration
Study: 8658340
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for eyelid dermatitis (specific treatments not detailed in the abstract)
Study: 4096071
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (IV)
Study: 24067260
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d THC
Study: 24067260
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d THC
Study: 24067260
Drug: 120 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/d THC
Study: 24067260
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/d THC)
Study: 23059145
Drug: d‐cycloserine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐cycloserine (50 mg)
Study: 20613539
Drug: Intravenous lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lornoxicam
Study: 16025322
Drug: Buprenorphine/naloxone 2/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone 2/0.5 mg
Study: 16025322
Drug: Buprenorphine/naloxone 8/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone 8/2 mg
Study: 16025322
Drug: Buprenorphine/naloxone 32/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone 32/8 mg
Study: 16025322
Drug: Buprenorphine/naloxone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (all doses)
Study: 1502490
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (Pepto-Bismol) - 2 tablets four times daily for 4 weeks
Study: 1502490
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate combined with clindamycin - 2 weeks of 300 mg clindamycin four times daily
Study: 6497564
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg test dose; 10 mg maintenance dose)
Study: 6497564
Drug: Thiothixene hydrochloride
Normalized name: Thiothixene Hydrochloride
DrugBank: Thiothixene (DB01623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiothixene hydrochloride (0.22 mg/kg test dose; 0.44 mg/kg maintenance dose)
Study: 6497564
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 mg test dose)
Study: 26966825
Drug: Maitland's Central
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maitland's Central postero-anterior vertebral pressure for thoracic spine (T1-T8) in addition to individualized treatment for low back pain and home exercise program (HEP) of breathing exercises
Study: 26966825
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment for low back pain and home exercise program (HEP) of breathing exercises
Study: 24986816
Drug: A1 beta-casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1 beta-casein milk (750 ml/day)
Study: 24986816
Drug: A2 beta-casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2 beta-casein milk (750 ml/day)
Study: 20855362
Drug: Lasmiditan (2.5-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (2.5-45 mg)
Study: 20855362
Drug: Lasmiditan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan (20 mg and higher)
Study: 17618954
Drug: Slow-release metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release metformin (SR)
Study: 17618954
Drug: Regular-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-release metformin (RR)
Study: 11023477
Drug: GM‐CSF (sargramostim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (sargramostim) 125 microgram/m(2) subcutaneously twice weekly for 6 months
Study: 8228207
Drug: Ro 42‐5892
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42‐5892 (600 mg orally, once a day)
Study: 8228207
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg orally, once a day)
Study: 2645889
Drug: Nalmefene, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene, 1.0 mg
Study: 2645889
Drug: Naloxone, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 1.0 mg
Study: 2645889
Drug: Saline, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, 1.0 mL
Study: 31894045
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride ointment
Study: 29050998
Drug: Detomidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1)
Study: 29050998
Drug: Methadone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.2 mg kg−1) alone (MET)
Study: 29050998
Drug: Detomidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (5 μg kg−1) alone (DET)
Study: 29050998
Drug: Detomidine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (2.5 μg kg−1) with methadone (0.2 mg kg−1) (MLD)
Study: 29050998
Drug: Detomidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1) (MMD)
Study: 29050998
Drug: Detomidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (10 μg kg−1) with methadone (0.2 mg kg−1) (MHD)
Study: 24107879
Drug: Adaptol, 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptol, 1500 mg daily divided into three doses for 8 weeks
Study: 21300344
Drug: Anastrozole at
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole at 1 mg/d
Study: 21300344
Drug: Anastrozole at
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole at 5 mg/d
Study: 21300344
Drug: Anastrozole at
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole at 10 mg/d
Study: 21300344
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate at 50 mg/d
Study: 20209968
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of starch capsules
Study: 17009251
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated equine estrogens (estrogen-alone trial)
Study: 17009251
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate (estrogen-plus-progestin trial)
Study: 15504193
Drug: Ephedrine 70
Normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 70 microg kg(‐1) administered intravenously 3 min before induction of anaesthesia.
Study: 15504193
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered intravenously 3 min before induction of anaesthesia (Control Group II).
Study: 9497795
Drug: Normoglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycaemia (blood glucose 5 mmol/l)
Study: 9497795
Drug: Acute hyperglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hyperglycaemia (aimed at 15 mmol/l)
Study: 9497795
Drug: Intrajejunal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrajejunal fat administration (1 g/h) during normoglycaemia
Study: 9497795
Drug: Intrajejunal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrajejunal fat administration (1 g/h) during hyperglycaemia
Study: 9497795
Drug: Fat administration
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat administration
Study: 3745847
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of liquid aluminum‐magnesium antacid (75 ml in five daily doses)
Study: 27496239
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral feeding (liquid oral diet for 2 weeks with gradually expanding daily maximums)
Study: 27496239
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding (enteral feeding via jejunostomy for 5 days followed by liquid oral diet)
Study: 22541652
Drug: Enoxaparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (low-molecular-weight heparin) in intraocular infusion fluid (BSS)
Study: 20228980
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel with carbopol as the thickening agent
Study: 20228980
Drug: 2% carbopol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carbopol gel
Study: 20228980
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide paste with poloxamer as the thickening agent
Study: 16025151
Drug: Control (hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hospital treatment)
Study: 10694766
Drug: Tofu diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofu diet (290 g/d)
Study: 10694766
Drug: Lean meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean meat diet (150 g/d)
Study: 9339181
Drug: OND+MPS (ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: OND+MPS (ondansetron 8 mg po before chemotherapy, methylprednisolone 120 mg IV before chemotherapy, followed by ondansetron 8 mg po and methylprednisolone 16 mg po on days 1-4)
Study: 9339181
Drug: TH (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH (conventional antiemetic treatment: benzamide plus corticosteroids with or without benzodiazepines)
Study: 8368408
Drug: Oral postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral postoperative corticosteroids
Study: 22414705
Drug: Placebo (sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill)
Study: 27793960
Drug: cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cabozantinib 60 mg orally once daily
Study: 27793960
Drug: everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus 10 mg orally once daily
Study: 25287751
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist liraglutide (1.2 mg per day)
Study: 23297810
Drug: Antidepressant cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant cessation advice given to general practitioners in cases of overtreatment.
Study: 8927668
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with full doses of clomipramine, fluoxetine, or fluvoxamine
Study: 8927668
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with half doses of clomipramine, fluoxetine, or fluvoxamine
Study: 8927668
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of pharmacotherapy
Study: 8927668
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from drug therapy (three subgroups)
Study: 6847173
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 300 mg/day
Study: 6847173
Drug: Rimantadine hydrochloride
Normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimantadine hydrochloride 300 mg/day
Study: 2921600
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 200 mg/day
Study: 6847173
Drug: Rimantadine hydrochloride
Normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimantadine hydrochloride 200 mg/day
Study: 30871894
Drug: Daily physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physiotherapy (mobilization, ambulation, shoulder exercises, breathing exercises)
Study: 30311724
Drug: 1.5% olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% olive ointment (n = 37)
Study: 30311724
Drug: 1.5% calendula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% calendula ointment (n = 39)
Study: 17500048
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg metformin and 2.5 mg glibenclamide per coated tablet (intervention group)
Study: 15337557
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy for ST‐PNETs
Study: 9352964
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus and infusion
Study: 8752612
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily for 6 months)
Study: 31248841
Drug: Duloxetine (30-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30-120 mg daily; mean 92.1 mg/day)
Study: 31248841
Drug: Desvenlafaxine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50-100 mg daily; mean 93.6 mg/day)
Study: 15459518
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program (Kegel exercises and interferential current) for 5 weeks, 15 sessions
Study: 16360958
Drug: Extended-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metoprolol succinate
Study: 9606617
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg 3 times daily
Study: 324257
Drug: Minoxidil (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (average dose 19.7 mg)
Study: 30407567
Drug: Muscimol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Muscimol infusion
Study: 24171300
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% cream, applied twice a day for 4 weeks
Study: 21737767
Drug: Bupropion 150
Normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 150 mg sustained-release once daily
Study: 19031231
Drug: Suggestion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suggestion to become a same-sex sibling; administered 2 challenges to the temporary delusion.
Study: 9383779
Drug: High-meat diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-meat diet (600 g)
Study: 9383779
Drug: Low-meat diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-meat diet (40 g)
Study: 9383779
Drug: High-meat diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-meat diet (600 g) with resistant starch (37 g)
Study: 8936955
Drug: Recombinant Interferon-2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant Interferon-2b (IFN-2b) at a dose of 5 MU/m2 three times a week, subcutaneously for 6 months
Study: 28679529
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of daily calories consumed at breakfast (BF group)
Study: 28679529
Drug: 50% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of daily calories consumed at dinner (D group)
Study: 23787719
Drug: Individualized salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized salt and fluid restriction (1.5 L fluid and 5 g salt daily) with dietary advice and support
Study: 16948674
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Impact Profile (OHIP14)
Study: 16948674
Drug: Oral Impacts
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Impacts on Daily Performance (OIDP)
Study: 8215552
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 7.5% sucrose
Study: 8215552
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of sterile water (control)
Study: 3139429
Drug: Terfenadine (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (full and half dosage)
Study: 3139429
Drug: Ranitidine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (standard and four-fold higher dose)